J&J's Janssen teams up with Intrexon for diabetes pill

Platform specialist Intrexon ($XON) has teamed up with Johnson & Johnson's ($JNJ) Janssen for a research collaboration to use its oral delivery system in therapies designed to treat Type 2 diabetes, obesity or metabolic disorders. The terms of the deal remain undisclosed.

Intrexon touts its ActoBiotics platform as one that can take on multiple aspects of Type 2 diabetes in a single pill and maintain glycemic control in the long term.

The pill delivers proteins and peptides to the oral and gastrointestinal tract using food-grade microbes called Lactococcus lactis engineered to contain the ActoBiotics drugs.

"I am very pleased we are partnering with Janssen to address Type 2 diabetes and related conditions," Intrexon Senior Vice President Samuel Broder said in a statement. "Through the use of Intrexon's proprietary ActoBiotics platform, we believe this collaboration will make a significant contribution to this substantial global health issue. The breadth of opportunity to treat an array of diseases with our versatile ActoBiotics technology continues to expand."

- here's the release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.